APA (7th ed.) Citation

van Asselt, A. D. I., Armstrong, N., Kimman, M., Peeters, A., McDermott, K., Stirk, L., . . . Grimm, S. E. (2023). Filgotinib for Treating Moderately to Severely Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 41(3), 239. https://doi.org/10.1007/s40273-023-01244-z

Chicago Style (17th ed.) Citation

van Asselt, Antoinette D. I., et al. "Filgotinib for Treating Moderately to Severely Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal." PharmacoEconomics 41, no. 3 (2023): 239. https://doi.org/10.1007/s40273-023-01244-z.

MLA (9th ed.) Citation

van Asselt, Antoinette D. I., et al. "Filgotinib for Treating Moderately to Severely Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal." PharmacoEconomics, vol. 41, no. 3, 2023, p. 239, https://doi.org/10.1007/s40273-023-01244-z.